Literature DB >> 19377974

Dissecting the urokinase activation pathway using urokinase-activated anthrax toxin.

Shihui Liu1, Thomas H Bugge, Arthur E Frankel, Stephen H Leppla.   

Abstract

Anthrax toxin is a three-part toxin secreted by Bacillus anthracis, consisting of protective antigen (PrAg), edema factor (EF), and lethal factor (LF). To intoxicate host mammalian cells, PrAg, the cell-binding moiety of the toxin, binds to cells and is then proteolytically activated by furin on the cell surface, resulting in the active heptameric form of PrAg. This heptamer serves as a protein-conducting channel that translocates EF and LF, the two enzymatic moieties of the toxin, into the cytosol of the cells where they exert cytotoxic effects. The anthrax toxin delivery system has been well characterized. The amino-terminal PrAg-binding domain of LF (residues 1-254, LFn) is sufficient to allow translocation of fused "passenger" polypeptides, such as the ADP-ribosylation domain of Pseudomonas exotoxin A, to the cytosol of the cells in a PrAg-dependent process. The protease specificity of the anthrax toxin delivery system can also be reengineered by replacing the furin cleavage target sequence of PrAg with other protease substrate sequences. PrAg-U2 is such a PrAg variant, one that is selectively activated by urokinase plasminogen activator (uPA). The uPA-dependent proteolytic activation of PrAg-U2 on the cell surface is readily detected by western blotting analysis of cell lysates in vitro, or cell or animal death in vivo. Here, we describe the use of PrAg-U2 as a molecular reporter tool to test the controversial question of what components are required for uPAR-mediated cell surface pro-uPA activation. The results demonstrate that both uPAR and plasminogen play critical roles in pro-uPA activation both in vitro and in vivo.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19377974      PMCID: PMC3393601          DOI: 10.1007/978-1-60327-003-8_10

Source DB:  PubMed          Journal:  Methods Mol Biol        ISSN: 1064-3745


  39 in total

1.  Optimal subsite occupancy and design of a selective inhibitor of urokinase.

Authors:  S H Ke; G S Coombs; K Tachias; D R Corey; E L Madison
Journal:  J Biol Chem       Date:  1997-08-15       Impact factor: 5.157

2.  Urokinase-type plasminogen activator is effective in fibrin clearance in the absence of its receptor or tissue-type plasminogen activator.

Authors:  T H Bugge; M J Flick; M J Danton; C C Daugherty; J Romer; K Dano; P Carmeliet; D Collen; J L Degen
Journal:  Proc Natl Acad Sci U S A       Date:  1996-06-11       Impact factor: 11.205

3.  Proteolytic inactivation of MAP-kinase-kinase by anthrax lethal factor.

Authors:  N S Duesbery; C P Webb; S H Leppla; V M Gordon; K R Klimpel; T D Copeland; N G Ahn; M K Oskarsson; K Fukasawa; K D Paull; G F Vande Woude
Journal:  Science       Date:  1998-05-01       Impact factor: 47.728

4.  Distinguishing the specificities of closely related proteases. Role of P3 in substrate and inhibitor discrimination between tissue-type plasminogen activator and urokinase.

Authors:  S H Ke; G S Coombs; K Tachias; M Navre; D R Corey; E L Madison
Journal:  J Biol Chem       Date:  1997-06-27       Impact factor: 5.157

Review 5.  The urokinase-type plasminogen activator system in cancer metastasis: a review.

Authors:  P A Andreasen; L Kjøller; L Christensen; M J Duffy
Journal:  Int J Cancer       Date:  1997-07-03       Impact factor: 7.396

6.  Plasminogen deficiency causes severe thrombosis but is compatible with development and reproduction.

Authors:  T H Bugge; M J Flick; C C Daugherty; J L Degen
Journal:  Genes Dev       Date:  1995-04-01       Impact factor: 11.361

7.  Physiological consequences of loss of plasminogen activator gene function in mice.

Authors:  P Carmeliet; L Schoonjans; L Kieckens; B Ream; J Degen; R Bronson; R De Vos; J J van den Oord; D Collen; R C Mulligan
Journal:  Nature       Date:  1994-03-31       Impact factor: 49.962

8.  The receptor for urokinase-type plasminogen activator is not essential for mouse development or fertility.

Authors:  T H Bugge; T T Suh; M J Flick; C C Daugherty; J Rømer; H Solberg; V Ellis; K Danø; J L Degen
Journal:  J Biol Chem       Date:  1995-07-14       Impact factor: 5.157

9.  Impaired wound healing in mice with a disrupted plasminogen gene.

Authors:  J Romer; T H Bugge; C Pyke; L R Lund; M J Flick; J L Degen; K Dano
Journal:  Nat Med       Date:  1996-03       Impact factor: 53.440

10.  Receptor-independent role of urokinase-type plasminogen activator in pericellular plasmin and matrix metalloproteinase proteolysis during vascular wound healing in mice.

Authors:  P Carmeliet; L Moons; M Dewerchin; S Rosenberg; J M Herbert; F Lupu; D Collen
Journal:  J Cell Biol       Date:  1998-01-12       Impact factor: 10.539

View more
  3 in total

1.  Inhibitory Effects of a Reengineered Anthrax Toxin on Canine Oral Mucosal Melanomas.

Authors:  Adriana Tomoko Nishiya; Marcia Kazumi Nagamine; Ivone Izabel Mackowiak da Fonseca; Andrea Caringi Miraldo; Nayra Villar Scattone; José Luiz Guerra; José Guilherme Xavier; Mário Santos; Cristina Oliveira Massoco de Salles Gomes; Jerrold Michael Ward; Shihui Liu; Stephen Howard Leppla; Thomas Henrik Bugge; Maria Lucia Zaidan Dagli
Journal:  Toxins (Basel)       Date:  2020-03-02       Impact factor: 4.546

2.  Anthrax toxin uptake by primary immune cells as determined with a lethal factor-beta-lactamase fusion protein.

Authors:  Haijing Hu; Stephen H Leppla
Journal:  PLoS One       Date:  2009-11-23       Impact factor: 3.240

3.  Inhibitory Effects of a Reengineered Anthrax Toxin on Canine and Human Osteosarcoma Cells.

Authors:  Jonathan Mackowiak da Fonseca; Ivone Izabel Mackowiak da Fonseca; Marcia Kazumi Nagamine; Cristina de Oliveira Massoco; Adriana Tomoko Nishiya; Jerrold Michael Ward; Shihui Liu; Stephen Howard Leppla; Thomas Henrik Bugge; Maria Lucia Zaidan Dagli
Journal:  Toxins (Basel)       Date:  2020-09-24       Impact factor: 4.546

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.